No Data
No Data
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
Revance Therapeutics Down Over 21%, on Pace for Largest Percent Decrease Since October 2021 -- Data Talk
Revance Therapeutics, Inc. (RVNC) is currently at $3.37, down $0.92 or 21.42% --Would be lowest close since April 25, 2024, when it closed at $3.29 --On pace for largest percent decrease since Oct.
No Data